News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

First Human Volunteer Immunized in Clinical Trial of Profectus BioSciences, Inc.’s Vesicular Stomatitis Virus-vectored HIV-1 Vaccine


1/4/2012 7:45:16 AM

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases, announced that a phase 1 study to test the safety and immunogenicity of a recombinant vesicular stomatitis virus (rVSV)-vectored HIV vaccine initiated on October 26th and, as of December 27th, 20 volunteers have been immunized. VSV is a type of RNA virus that can infect both insects and mammals. It is commonly used in laboratory settings as a gene delivery vector without the potential for integration, a characteristic that provides a safety advantage in vaccine applications. The first studies to demonstrate the potential of rVSV as an HIV vaccine vector were performed in the laboratories of Dr. John K. Rose at Yale University more than a decade ago. The recombinant version used in this new vaccine study is able to replicate in human cells, but has been attenuated (weakened) so as not to cause illness in animals or humans.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES